STAT3: A Novel Molecular Mediator of Resistance to Chemoradiotherapy

STAT3: A Novel Molecular Mediator of Resistance to Chemoradiotherapy

Chemoradiotherapy (CRT) represents a standard treatment for many human cancers, frequently combined with radical surgical resection. However, a considerable percentage of primary cancers are at least partially resistant to CRT, which represents a substantial clinical problem, because it exposes canc...

Full description

Bibliographic Details
Main Authors:	Melanie Spitzner, Reinhard Ebner, Hendrik A. Wolff, B. Michael Ghadimi, Jürgen Wienands, Marian Grade
Format:	Article
Language:	English
Published:	MDPI AG 2014-09-01
Series:	Cancers
Subjects:	STAT3 cancer radiotherapy chemoradiotherapy chemoradiotherapy-resistance chemoradiotherapy-sensitization molecular target
Online Access:	http://www.mdpi.com/2072-6694/6/4/1986

Similar Items

NOTCH Activation via gp130/STAT3 Signaling Confers Resistance to Chemoradiotherapy
by: Kristin Koerdel, et al.
Published: (2021-01-01)

Firsthand experience of chemoradiotherapy in patients with localized small cell lung cancer. Retrospective assessment
by: A. E. Kuzminov, et al.
Published: (2020-07-01)

Preoperative long-course chemoradiotherapy plus adjuvant chemotherapy versus short-course radiotherapy without adjuvant chemotherapy both with delayed surgery for stage II–III resectable rectal cancer: 5-Year survival data of a randomized controlled trial
by: Laura Kairevičė, et al.
Published: (2017-01-01)

The treatment outcome of definitive chemoradiotherapy in patients with esophageal squamous cell carcinoma
by: Mahdi Seilanian Toosi, et al.
Published: (2007-10-01)

Outcome and toxicity of radical radiotherapy or concurrent Chemoradiotherapy for elderly cervical cancer women
by: Weiping Wang, et al.
Published: (2017-08-01)

Efficacy of modified neoadjuvant chemoradiotherapy in locally advanced rectal cancer: A single institution experience in Taiwan
by: Yi-Ying Wu, et al.
Published: (2014-01-01)

Outcome and prognostic factors in cervical cancer patients treated with surgery and concurrent chemoradiotherapy: a retrospective study
by: Yan-Mei Liu, et al.
Published: (2018-01-01)

Impact of Adjuvant Chemoradiotherapy on Survival of Resected Pancreatic Adenocarcinoma Cancer: A Surveillance, Epidemiology and End Results (SEER) Analysis
by: Xiaomao Shi, et al.
Published: (2021-07-01)

2-CONSERVATIVE TREATMENT OF RECTAL ADENOCARCINOMA AFTER NEOADJUVANT CHEMORADIOTHERAPY, IS IT ACCEPTABLE?
by: Majeed H Alwan
Published: (2009-06-01)

STAT3β Enhances Sensitivity to Concurrent Chemoradiotherapy by Inducing Cellular Necroptosis in Esophageal Squamous Cell Carcinoma
by: Zhen-Yuan Zheng, et al.
Published: (2021-02-01)

THE RATE OF PATHOLOGICAL COMPLETE RESPONSE AND LONG-TERM OUTCOMES OF COMBINED TREATMENT FOR MIDDLE AND LOW RECTAL CANCER
by: S. M. Demidov, et al.
Published: (2015-02-01)

Comparison of Auditory Effects after IMRT with Concurrent Cisplatin for Locally Advanced Head and Neck Cancer
by: Sushil Kumar Aggarwal, et al.
Published: (2019-10-01)

The Impact of Active Nutritional Support for Head and Neck Cancer Patients Receiving Concurrent Chemoradiotherapy
by: Vutisiri Veerasarn, et al.
Published: (2019-12-01)

Preoperative chemoradiotherapy for locally advanced gastric cancer
by: Pepek Joseph M, et al.
Published: (2013-01-01)

Frequency of chemoradiotherapy-induced mucositis and related risk factors in patients with the head-and-neck cancers: A survey in the North of Iran
by: Hamid Saeidi Saedi, et al.
Published: (2019-01-01)

Effectiveness of image‐guided radiotherapy for locally advanced lung cancer patients treated with definitive concurrent chemoradiotherapy
by: Ji‐An Liang, et al.
Published: (2020-09-01)

Erythropoietins (Epostim®) during chemoradiotherapy for malignancies in anemic patients
by: V. A. Titova, et al.
Published: (2014-08-01)

The Contribution of Adding Chemoradiotherapy to Adjuvant Chemotherapy in Pancreatic Cancer Patients
by: Gökhan Uçar, et al.
Published: (2020-12-01)

Influence of Chemoradiotherapy Strategies and Factors on the Five-Years Survival of Patients with Esophageal Cancer
by: Seyed Kazem Mirinezhad, et al.
Published: (2014-08-01)

Safety and efficacy of nimotuzumab combined with chemoradiotherapy in Chinese patients with locally advanced cervical cancer
by: Chen Y, et al.
Published: (2017-08-01)

Elderly Patients with Locally Advanced and Unresectable Non-Small-Cell Lung Cancer May Benefit from Sequential Chemoradiotherapy
by: Magdalena Zaborowska-Szmit, et al.
Published: (2021-09-01)

Concurrent chemoradiotherapy using cisplatin, tegafur, and leucovorin for advanced squamous cell carcinoma of the hypopharynx and oropharynx
by: Hung-Ming Wang, et al.
Published: (2014-06-01)

The Impact of Radiotherapy Dose in Patients with Locally Advanced Esophageal Squamous Cell Carcinoma Receiving Preoperative Chemoradiotherapy
by: Chien-Ming Lo, et al.
Published: (2021-03-01)

Current principles for the planning and performance of radiotherapy in the conservative treatment of locally advanced cancer of the cervix uteri
by: Yu. M. Kreynina, et al.
Published: (2014-07-01)

Phase I Radiation Dose-Escalation Study to Investigate the Dose-Limiting Toxicity of Concurrent Intra-Arterial Chemotherapy for Unresectable Hepatocellular Carcinoma
by: Yeona Cho, et al.
Published: (2020-06-01)

Factors affecting survival after concurrent chemoradiation therapy for advanced hepatocellular carcinoma: a retrospective study
by: Ja Kyung Kim, et al.
Published: (2017-08-01)

ADJUVANT CHEMOTHERAPY AFTER RECTAL CANCER CHEMORADIOTHERAPY
by: M. Yu. Fedyanin, et al.
Published: (2015-02-01)

Tracheoesophageal Fistula Closed by Chemoradiotherapy in Lung Cancer
by: Takayuki Honda, et al.
Published: (2011-07-01)

Chemoradiotherapy-Associated Myelosuppression: A Retrospective Analysis of Risk Factors for Patients with Non-Small Cell Lung Cancer
by: Ufuk Mehmet Yılmaz, et al.
Published: (2015-04-01)

Concurrent cisplatin-based chemoradiotherapy versus exclusive radiotherapy in high-risk cervical cancer: a meta-analysis
by: Meng XY, et al.
Published: (2016-03-01)

Chemoradiotherapy versus surgery followed by postoperative radiotherapy in tonsil cancer: Korean Radiation Oncology Group (KROG) study
by: Sanghyuk Song, et al.
Published: (2017-08-01)

BIOLOGICAL MARKERS OF RECTAL CANCER NEOADJUVANT CHEMORADIOTHERAPY EFFICACY
by: M. Yu. Fedyanin, et al.
Published: (2015-02-01)

To compare the effect of conventional radiotherapy versus concurrent chemoradiotherapy on the thyroid gland after external beam radiotherapy in head-and-neck carcinoma
by: Surabhi Gupta, et al.
Published: (2021-01-01)

Chemoradiotherapy for locally advanced pancreatic cancer patients: is it still an open question?
by: Emilia Sawicka, et al.
Published: (2016-06-01)

S-1–Based Chemoradiotherapy Followed by Consolidation Chemotherapy With S-1 in Elderly Patients With Esophageal Squamous Cell Carcinoma: A Multicenter Phase II Trial
by: Xin Wang, et al.
Published: (2020-08-01)

Optimal time intervals between preoperative radiotherapy or chemoradiotherapy and surgery in rectal cancer?
by: Bengt eGlimelius
Published: (2014-04-01)

Efficacy and safety of recombinant human endostatin combined with radiotherapy or chemoradiotherapy in patients with locally advanced non-small cell lung cancer: a pooled analysis
by: Shu-Ling Zhang, et al.
Published: (2020-08-01)

Life expectancy with perioperative chemotherapy and chemoradiotherapy for locally advanced gastric adenocarcinoma
by: Sadighi S, et al.
Published: (2008-12-01)

High survivin expression as a risk factor in patients with anal carcinoma treated with concurrent chemoradiotherapy
by: Fraunholz Ingeborg, et al.
Published: (2012-06-01)

Outcomes and prognostic factors for patients with cervical esophageal cancer undergoing definitive radiotherapy or chemoradiotherapy
by: Xin-xin Du, et al.
Published: (2019-03-01)

Cannot write session to /tmp/vufind_sessions/sess_mcomblgaaakht6me60lh6j8r6p